- Home
- RGC
as 11-03-2025 1:41pm EST
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
| Founded: | 2014 | Country: | Hong Kong |
| Employees: | N/A | City: | N/A |
| Market Cap: | 8.4B | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 194.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.09 - $83.60 | Next Earning Date: | 10-24-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Regencell Bioscience Holdings Limited News
RGC Breaking Stock News: Dive into RGC Ticker-Specific Updates for Smart Investing
Insider Monkey
a month ago
Regencell Bioscience Holdings Limited (RGC) Added to S&P Global BMI Index Amid Positive ADHD/ASD Trial Results
Bloomberg
2 months ago
Nasdaq Revamps Listing Rules for Small IPOs and Chinese Firms
GuruFocus.com
4 months ago
Regencell's 82,000% Surge: The $33 Billion Stock Rally That Nobody Can Explain
Bloomberg
4 months ago
Mystery $33 Billion Medicine Fortune Collapses in Days
MT Newswires
4 months ago
Top Premarket Gainers
MT Newswires
4 months ago
Top Premarket Decliners
Simply Wall St.
4 months ago
Regencell Bioscience Holdings (NasdaqCM:RGC) Announces 38:1 Stock Split Effective June 2025
GuruFocus.com
5 months ago
The 46,000% Biotech Rocket: How a No-Revenue Stock Hit $30 Billion
Compare RGC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RGC Regencell Bioscience Holdings Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.